Barclays PLC Buys 75,624 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Barclays PLC raised its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 74.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 177,077 shares of the company's stock after purchasing an additional 75,624 shares during the period. Barclays PLC owned approximately 0.21% of Atea Pharmaceuticals worth $593,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in AVIR. Intech Investment Management LLC acquired a new position in shares of Atea Pharmaceuticals during the third quarter worth $36,000. Dynamic Technology Lab Private Ltd acquired a new position in Atea Pharmaceuticals during the 3rd quarter worth about $37,000. China Universal Asset Management Co. Ltd. lifted its holdings in Atea Pharmaceuticals by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,237 shares of the company's stock worth $54,000 after buying an additional 6,343 shares during the period. Zacks Investment Management bought a new stake in shares of Atea Pharmaceuticals in the 3rd quarter valued at about $80,000. Finally, SG Americas Securities LLC increased its stake in shares of Atea Pharmaceuticals by 117.9% in the third quarter. SG Americas Securities LLC now owns 30,612 shares of the company's stock valued at $103,000 after buying an additional 16,561 shares during the period. Institutional investors and hedge funds own 86.67% of the company's stock.

Insider Buying and Selling

In related news, Director Franklin M. Berger sold 359,606 shares of the company's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the sale, the director now owns 451,897 shares in the company, valued at $1,287,906.45. This represents a 44.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 17.80% of the stock is owned by insiders.

Atea Pharmaceuticals Stock Performance

Shares of AVIR traded up $0.04 during mid-day trading on Friday, reaching $3.37. 337,674 shares of the company were exchanged, compared to its average volume of 471,099. The business has a 50 day simple moving average of $3.25 and a two-hundred day simple moving average of $3.46. The stock has a market capitalization of $284.63 million, a PE ratio of -1.63 and a beta of 0.20. Atea Pharmaceuticals, Inc. has a 52 week low of $2.75 and a 52 week high of $4.60.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.13. During the same quarter in the prior year, the business posted ($0.40) EPS. On average, analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.